About the Company
Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion. Bonney, a native of the Greater Boston area, graduated from Bates College before entering the pharmaceutical industry. He was hired by Biogen in 1995 eventually becoming the company's vice president for Sales and Marketing. During his tenure at the company he developed Avonex, which was according to MarketWatch, one of the most successful drugs in biotechnology history. He was appointed the chief operating officer of Cubist Pharmaceuticals in 2003 and served in the position for one year before becoming chief executive. His tenure as CEO saw mixed profit levels, criticism, and increased market volatility as well as the development and release of Cubicin, the most profitable launch of an antibiotic in the history of the United States. Bonney serves as an advisor to former Prime Minister David Cameron's Commission on Antimicrobial Resistance (AMR).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XFOR News
X4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62
The average one-year price target for X4 Pharmaceuticals (NasdaqCM:XFOR) has been revised to 3.62 / share. This is an ...
X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment ...
X4 Pharmaceuticals: PDUFA Excitement Ahead
X4 Pharmaceuticals, Inc. is awaiting an FDA decision on its lead molecule mavorixafor for the treatment of WHIM syndrome. Mavorixafor is a powerful immune system booster with potential in treating ...
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript
X4 Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.15. XFOR isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
X4 Pharmaceuticals Inc (XFOR) Stock: A Guide to the Market Trend
Get insider insights on their strengths, past performance, and future potential. Make informed investment decisions and secure your future growth.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used ...
XFOR X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
X4 Pharmaceuticals Inc XFOR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
X4 Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...